CYP4F11

Across TCGA pan-cancer cohorts, CYP4F11 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYP4F11 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CYP4F11 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CYP4F11 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SARC show a favorable association.

BLCA, SKCM, and PRAD are the cancer types where CYP4F11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.083	0.572	<.001	12	view →
SKCM	DFS	Median	III,IV	0.259	0.704	<.001	11	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	III,IV	0.903	0.775	.031	2	view →
SARC	DFS	Median	All	1.000	0.503	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYP4F11–BLCA (DFS)

Open the BLCA breakdown →